H Niitani

568 total citations
53 papers, 431 citations indexed

About

H Niitani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, H Niitani has authored 53 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in H Niitani's work include Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (19 papers) and Nausea and vomiting management (13 papers). H Niitani is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Lung Cancer Treatments and Mutations (19 papers) and Nausea and vomiting management (13 papers). H Niitani collaborates with scholars based in Japan, Greece and Pakistan. H Niitani's co-authors include Kazuo Hasegawa, T Taguchi, M. Fukuoka, Shunichi Negoro, H Furue, Yuichi Kurita, A Wakui, Kiyoyuki Furuse, Akihiro Suzuki and Toshihiro Nakabayashi and has published in prestigious journals such as Circulation, Journal of Molecular and Cellular Cardiology and Lung Cancer.

In The Last Decade

H Niitani

49 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H Niitani Japan 10 316 188 183 63 54 53 431
Comis Rl United States 6 190 0.6× 151 0.8× 60 0.3× 39 0.6× 57 1.1× 11 337
Yoshifumi Soejima Japan 8 309 1.0× 95 0.5× 269 1.5× 43 0.7× 50 0.9× 27 440
Wittes Re United States 12 215 0.7× 87 0.5× 71 0.4× 36 0.6× 112 2.1× 24 377
S. Nagel Germany 10 239 0.8× 76 0.4× 207 1.1× 46 0.7× 50 0.9× 29 421
M. Westerhausen Germany 11 212 0.7× 116 0.6× 87 0.5× 52 0.8× 24 0.4× 50 428
D. Mignard France 7 289 0.9× 216 1.1× 92 0.5× 83 1.3× 43 0.8× 10 442
Hiroshi Takatani Japan 15 382 1.2× 264 1.4× 196 1.1× 63 1.0× 111 2.1× 42 559
Juergen Tepel Germany 12 130 0.4× 193 1.0× 149 0.8× 211 3.3× 56 1.0× 20 529
P. Lippe Italy 11 294 0.9× 154 0.8× 172 0.9× 42 0.7× 19 0.4× 20 426
Gonzalo Gomez-Abuin Argentina 6 182 0.6× 94 0.5× 84 0.5× 78 1.2× 22 0.4× 10 350

Countries citing papers authored by H Niitani

Since Specialization
Citations

This map shows the geographic impact of H Niitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Niitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Niitani more than expected).

Fields of papers citing papers by H Niitani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H Niitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Niitani. The network helps show where H Niitani may publish in the future.

Co-authorship network of co-authors of H Niitani

This figure shows the co-authorship network connecting the top 25 collaborators of H Niitani. A scholar is included among the top collaborators of H Niitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H Niitani. H Niitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kobayashi, Kunihiko, M. Fukuoka, Kenji Takeuchi, et al.. (2002). Phase I studies of nogitecan hydrochloride for Japanese. International Journal of Clinical Oncology. 7(3). 177–186. 7 indexed citations
2.
Niitani, H. (1999). [Navelbine (vinorelbine): a review of its antitumor activity and toxicity in clinical studies].. PubMed. 26(10). 1495–507. 2 indexed citations
3.
Ishihara, Yoko, Ken Kobayashi, Shuichi Yoneda, et al.. (1996). [The development of a new QOL Questionnaire on chemotherapy - induced emesis and vomiting--investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study].. PubMed. 23(6). 745–55. 2 indexed citations
4.
Kobayashi, Kazuhiro, Yuki Ishihara, T Matsuda, et al.. (1996). [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study].. PubMed. 23(6). 757–71. 1 indexed citations
5.
Taguchi, Tetsuya, Kiyoyuki Furuse, M. Fukuoka, et al.. (1996). [LY188011 phase I study. Research Group of Gemcitabine (LY188011)].. PubMed. 23(8). 1011–8. 5 indexed citations
6.
Furue, H, et al.. (1995). [Clinical phase II study of tropisetron capsule in the treatment of nausea and vomiting induced by anti-cancer drugs].. PubMed. 22(8). 1073–86. 1 indexed citations
8.
Majima, H, Shigeru Tsukagoshi, H Furue, et al.. (1993). [Phase I Study of RA-700. RA-700 Clinical Study Group].. PubMed. 20(1). 67–78. 5 indexed citations
9.
Ariyoshi, Y, Kay Y. Ota, T Taguchi, et al.. (1992). [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].. PubMed. 19(12). 2057–70. 3 indexed citations
10.
Taguchi, T, Ota K, H Furue, et al.. (1992). [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].. PubMed. 19(9). 1359–74.
11.
Furue, H, T Taguchi, Ota K, et al.. (1992). [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].. PubMed. 19(11). 1891–903. 1 indexed citations
12.
Taguchi, T, H Furue, H Niitani, et al.. (1992). [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].. PubMed. 19(12). 2041–55. 3 indexed citations
13.
Furue, H, T Taguchi, H Niitani, et al.. (1992). [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].. PubMed. 19(11). 1879–90.
14.
Kubota, Kazuo, Kiyoyuki Furuse, & H Niitani. (1991). A late phase II study of navelbine (vinorelbine), a new vinca alkaloid derivative, in non small cell lung cancer. Lung Cancer. 7. 117–117. 9 indexed citations
15.
Shibuya, Masahiko, et al.. (1990). [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].. PubMed. 17(4 Pt 2). 950–6. 1 indexed citations
16.
Taguchi, T, et al.. (1990). [Phase I clinical study of CPT-11. Research group of CPT-11].. PubMed. 17(1). 115–20. 58 indexed citations
17.
Ozawa, M., et al.. (1988). [Effects of bathing on cardiac function in patients with myocardial infarction: hemodynamic and Doppler echocardiographic studies].. PubMed. 18(4). 979–87. 3 indexed citations
18.
Konno, Noburu, et al.. (1987). Metabolic changes in non-ischemic myocardium under pump failure complicated in acute myocardial infarction. Journal of Molecular and Cellular Cardiology. 19. S26–S26. 3 indexed citations
19.
Kato, Kazuo, H Niitani, Takeharu Kanazawa, Katsuro Shimomura, & S. Toyama. (1985). Clinical Evaluation of Bisoprolol in Patients with Stable Angina Pectoris: A Preliminary Report. Journal of Cardiovascular Pharmacology. 8. S154–S159. 3 indexed citations
20.
Kimura, Kiminori, Kazuki Yamada, & H Niitani. (1985). [Phase I clinical study of NK 171 (etoposide)].. PubMed. 12(4). 851–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026